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Abstract
Proteinase-activated receptors (PARs, nomenclature as agreed by the NC-IUPHAR Subcommittee on
Proteinase-activated Receptors [35]) are unique members of the GPCR superfamily activated by proteolytic
cleavage of their amino terminal exodomains. Agonist proteinase-induced hydrolysis unmasks a tethered ligand
(TL) at the exposed amino terminus, which acts intramolecularly at the binding site in the body of the receptor to
effect transmembrane signalling. TL sequences at human PAR1-4 are SFLLRN-NH2, SLIGKV-NH2, TFRGAP-
NH2 and GYPGQV-NH2, respectively. With the exception of PAR3, synthetic peptides with these sequences (as
carboxyl terminal amides) are able to act as agonists at their respective receptors. Several proteinases,
including neutrophil elastase, cathepsin G and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such
that they cleave the exodomain of the receptor without inducing activation of Gαq-coupled calcium signalling,
thereby preventing activation by activating proteinases but not by agonist peptides. Neutrophil elastase (NE)
cleavage of PAR1 and PAR2 can however activate MAP kinase signaling by exposing a TL that is different from
the one revealed by trypsin [73]. PAR2 ectivation by NE regulates inflammation and pain responses [101, 65]
and triggers mucin secretion from airway epithelial cells [102].
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